DV
Dividend Vision

ATHE — Alterity Therapeutics Ltd

Alterity Therapeutics Ltd (ATHE)

Total return is -99.3% over the past 23.9 years, 1354.3 points behind SPY at 1255.0%. Its deepest 1-year drawdown was 44.4%.

Alterity Therapeutics Limited is a biopharmaceutical company engaged in research and development of treatments for neurodegenerative disorders, including Parkinson's disease and Multiple System Atrophy. The company's lead candidate, ATH434, has completed Phase II clinical trials, with additional Phase II studies underway for MSA indications. Alterity does not currently distribute, making it of interest primarily to growth-oriented investors rather than those seeking current income.

ATHE key facts

Asset type
Stock
Asset class
Equity
Inception date
09/05/2002
Last close
$4.79
Market cap
$90,265,960
Average volume
7400.0
Beta
-0.03
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.63